Matthew Sykes
Stock Analyst at Goldman Sachs
(3.91)
# 560
Out of 4,760 analysts
188
Total ratings
49.62%
Success rate
8.97%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $22 → $11 | $10.23 | +7.53% | 3 | Mar 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $49 → $56 | $35.84 | +56.25% | 13 | Feb 21, 2025 | |
| WGS GeneDx Holdings | Maintains: Neutral | $70 → $80 | $89.66 | -10.77% | 11 | Feb 19, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $1.75 → $1.5 | $1.39 | +7.91% | 5 | Feb 18, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $20 → $18 | $9.09 | +98.13% | 6 | Jan 28, 2025 | |
| NTRA Natera | Maintains: Buy | $160 → $190 | $132.63 | +43.26% | 13 | Jan 28, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $29 → $18 | $9.60 | +87.50% | 10 | Jan 28, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $220 → $190 | $175.12 | +8.50% | 3 | Jan 23, 2025 | |
| NAUT Nautilus Biotechnology | Downgrades: Sell | $2.25 → $1.75 | $1.14 | +53.51% | 5 | Dec 5, 2024 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Sell | $7 → $4.25 | $2.86 | +48.60% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $30.38 | +21.79% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $60 | $47.40 | +26.58% | 4 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $44.97 | +44.54% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $188.78 | +32.43% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $14 | $10.59 | +32.20% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $280 | $182.72 | +53.24% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $35 | $18.09 | +93.48% | 9 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $250 | $205.23 | +21.81% | 4 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $55 | $36.71 | +49.82% | 9 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $7.28 | +229.67% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,294.40 | +0.43% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $6.95 | +72.66% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $526.80 | +21.49% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $4.36 | +129.36% | 8 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $17.28 | +50.46% | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $121.90 | +18.95% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $38.89 | - | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $105 | $118.23 | -11.19% | 1 | Oct 31, 2023 |
Fortrea Holdings
Mar 4, 2025
Maintains: Neutral
Price Target: $22 → $11
Current: $10.23
Upside: +7.53%
Guardant Health
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $35.84
Upside: +56.25%
GeneDx Holdings
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $89.66
Upside: -10.77%
Pacific Biosciences of California
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.39
Upside: +7.91%
NeoGenomics
Jan 28, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $9.09
Upside: +98.13%
Natera
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $132.63
Upside: +43.26%
Myriad Genetics
Jan 28, 2025
Maintains: Buy
Price Target: $29 → $18
Current: $9.60
Upside: +87.50%
Charles River Laboratories International
Jan 23, 2025
Maintains: Buy
Price Target: $220 → $190
Current: $175.12
Upside: +8.50%
Nautilus Biotechnology
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.14
Upside: +53.51%
Maravai LifeSciences Holdings
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.86
Upside: +48.60%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $30.38
Upside: +21.79%
Dec 5, 2024
Upgrades: Neutral
Price Target: $60
Current: $47.40
Upside: +26.58%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $44.97
Upside: +44.54%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $188.78
Upside: +32.43%
Oct 30, 2024
Maintains: Sell
Price Target: $16 → $14
Current: $10.59
Upside: +32.20%
Oct 25, 2024
Maintains: Buy
Price Target: $370 → $280
Current: $182.72
Upside: +53.24%
Oct 16, 2024
Maintains: Buy
Price Target: $26 → $35
Current: $18.09
Upside: +93.48%
Jul 24, 2024
Maintains: Neutral
Price Target: $225 → $250
Current: $205.23
Upside: +21.81%
Jul 9, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $36.71
Upside: +49.82%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $7.28
Upside: +229.67%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,294.40
Upside: +0.43%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $6.95
Upside: +72.66%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $526.80
Upside: +21.49%
Feb 29, 2024
Maintains: Buy
Price Target: $9 → $10
Current: $4.36
Upside: +129.36%
Dec 7, 2023
Maintains: Buy
Price Target: $23 → $26
Current: $17.28
Upside: +50.46%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $121.90
Upside: +18.95%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $38.89
Upside: -
Oct 31, 2023
Maintains: Buy
Price Target: $120 → $105
Current: $118.23
Upside: -11.19%